Trevi Therapeutics Files 8-K
Ticker: TRVI · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1563880
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Trevi Therapeutics filed an 8-K on Oct 3rd, check for 'Other Events'.
AI Summary
Trevi Therapeutics, Inc. filed an 8-K on October 4, 2024, reporting an event that occurred on October 3, 2024. The filing is categorized under 'Other Events' and does not specify any significant financial transactions or corporate changes in the provided text.
Why It Matters
This filing indicates a routine update or event disclosure by Trevi Therapeutics, Inc. to the SEC, requiring investor attention for any material information contained within the full report.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain information that inherently poses a high risk.
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant
- 0000950170-24-112729 (other) — Accession Number
- 20241003 (date) — Report Date
- 20241004 (date) — Filing Date
- 195 Church Street, 16th Floor New Haven, Connecticut 06510 (address) — Principal Executive Offices
- (203) 304-2499 (phone_number) — Registrant's telephone number
FAQ
What is the exact date of the event reported in the 8-K filing?
The date of the earliest event reported is October 3, 2024.
What is the name of the company filing the 8-K?
The company filing the 8-K is Trevi Therapeutics, Inc.
Under which item information is this 8-K filed?
This 8-K filing is categorized under 'Other Events'.
What is the principal executive office address of Trevi Therapeutics, Inc.?
The principal executive offices are located at 195 Church Street, 16th Floor, New Haven, Connecticut 06510.
What is the telephone number for Trevi Therapeutics, Inc.?
The registrant's telephone number, including area code, is (203) 304-2499.
Filing Stats: 863 words · 3 min read · ~3 pages · Grade level 14.4 · Accepted 2024-10-04 08:07:28
Key Financial Figures
- $0.001 — e on which registered Common stock, $0.001 par value per share TRVI The Nasdaq
Filing Documents
- trvi-20241003.htm (8-K) — 45KB
- 0000950170-24-112729.txt ( ) — 164KB
- trvi-20241003.xsd (EX-101.SCH) — 28KB
- trvi-20241003_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events On October 3, 2024, Trevi Therapeutics, Inc. (the "Company") announced the following updates on its clinical development programs. The Company's Phase 2b CORAL trial for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis has enrolled 50% of the targeted study enrollment, which is the number of patients needed for the pre-specified sample size re-estimation ("SSRE"). The SSRE will be performed once the last of these patients complete the six weeks of treatment. The outcome of the SSRE result is expected in December 2024. The three potential SSRE outcomes are: maintain current sample size (N=160), upsize within a pre-specified range, or evaluate for futility. Assuming no adjustments are made to the sample size, topline results are expected in the first half of 2025. The Company's Human Abuse Potential study completed dosing. Topline results are expected in December 2024. The Company's Phase 2a RIVER trial for the treatment of refractory chronic cough has enrolled the planned sample size but remains open to allow for additional enrollment in both arms to approximate the stratification targets. Topline results are now expected in the first quarter of 2025.
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREVI THERAPEUTICS, INC. Date: October 3, 2024 By: /s/ Lisa Delfini Name: Lisa Delfini Title: Chief Financial Officer